دورية أكاديمية
Gene expression responses to anti-tuberculous drugs in a whole blood model.
العنوان: | Gene expression responses to anti-tuberculous drugs in a whole blood model. |
---|---|
المؤلفون: | Kwan PKW; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower Block Level 10, 1E Kent Ridge Road, Singapore, 119228, Singapore., Lin W; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower Block Level 10, 1E Kent Ridge Road, Singapore, 119228, Singapore., Naim ANM; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore., Periaswamy B; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore., De Sessions PF; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore., Hibberd ML; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore.; London School of Hygiene & Tropical Medicine, London, UK.; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Paton NI; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, NUHS Tower Block Level 10, 1E Kent Ridge Road, Singapore, 119228, Singapore. nick_paton@nuhs.edu.sg.; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore. nick_paton@nuhs.edu.sg.; London School of Hygiene & Tropical Medicine, London, UK. nick_paton@nuhs.edu.sg.; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. nick_paton@nuhs.edu.sg. |
المصدر: | BMC microbiology [BMC Microbiol] 2020 Apr 07; Vol. 20 (1), pp. 81. Date of Electronic Publication: 2020 Apr 07. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 100966981 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2180 (Electronic) Linking ISSN: 14712180 NLM ISO Abbreviation: BMC Microbiol Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: London : BioMed Central, [2001- |
مواضيع طبية MeSH: | Antitubercular Agents/*pharmacology , Bacterial Proteins/*genetics , Blood/*microbiology , Gene Expression Profiling/*methods , Mycobacterium tuberculosis/*growth & development , Sputum/*microbiology, Drug Combinations ; Drug Repositioning ; Ethambutol/pharmacology ; Gene Expression Regulation, Bacterial/drug effects ; Humans ; Isoniazid/pharmacology ; Models, Biological ; Mycobacterium tuberculosis/drug effects ; Oligonucleotide Array Sequence Analysis ; Pyrazinamide/pharmacology ; Rifampin/pharmacology |
مستخلص: | Background: There is a need for better tools to evaluate new or repurposed TB drugs. The whole blood bactericidal activity (WBA) assay has been advocated for this purpose. We investigated whether transcriptional responses in the WBA assay resemble TB responses in vivo, and whether the approach might additionally reveal mechanisms of action. Results: 1422 of 1798 (79%) of differentially expressed genes in WBA incubated with the standard combination of rifampicin, isoniazid, pyrazinamide and ethambutol were also expressed in sputum (P < 0.0001) obtained from patients taking the same combination of drugs; these comprised well-established treatment-response genes. Gene expression profiles in WBA incubated with the standard drugs individually, or with moxifloxacin or faropenem (with amoxicillin and clavulanic acid) clustered by individual drug exposure. Distinct pathways were detected for individual drugs, although only with isoniazid did these relate to known mechanisms of drug action. Conclusions: Substantial agreement between whole blood cultures and sputum and the ability to differentiate individual drugs suggest that transcriptomics may add value to the whole blood assay for evaluating new TB drugs. |
References: | J Biol Chem. 2004 Sep 17;279(38):40174-84. (PMID: 15247240) J Infect Dis. 2003 Jan 15;187(2):270-8. (PMID: 12552451) Nucleic Acids Res. 2003 Feb 15;31(4):e15. (PMID: 12582260) Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792) Eur Respir J. 2016 Apr;47(4):1229-34. (PMID: 26743484) J Exp Med. 2016 May 2;213(5):809-25. (PMID: 27114608) Antimicrob Agents Chemother. 2003 Sep;47(9):2903-13. (PMID: 12936993) Antimicrob Agents Chemother. 2011 Feb;55(2):567-74. (PMID: 21078950) ACS Infect Dis. 2017 Nov 10;3(11):807-819. (PMID: 28991455) PLoS One. 2013 Jul 31;8(7):e69191. (PMID: 23935951) BMC Med. 2016 Apr 07;14:68. (PMID: 27055815) Adv Drug Deliv Rev. 2016 Jul 1;102:116-22. (PMID: 26827911) PLoS One. 2014 Apr 14;9(4):e94462. (PMID: 24732289) PLoS One. 2019 May 17;14(5):e0216616. (PMID: 31100071) J Infect Dis. 2010 Sep 1;202(5):745-51. (PMID: 20629533) Drugs. 2014 Jun;74(8):839-54. (PMID: 24846578) Antimicrob Agents Chemother. 2009 Oct;53(10):4138-46. (PMID: 19596878) Antimicrob Agents Chemother. 2013 Apr;57(4):1941-3. (PMID: 23335736) N Engl J Med. 2016 Jul 28;375(4):393-4. (PMID: 27433841) J Infect Dis. 2001 Apr 15;183(8):1300-3. (PMID: 11262217) Antimicrob Agents Chemother. 2014 Jun;58(6):3306-11. (PMID: 24687496) Antimicrob Agents Chemother. 1999 Jun;43(6):1508-10. (PMID: 10348784) Genome Biol. 2003;4(5):P3. (PMID: 12734009) Lancet Infect Dis. 2013 Apr;13(4):362-72. (PMID: 23531389) Antimicrob Agents Chemother. 2017 Sep 22;61(10):. (PMID: 28739782) J Antimicrob Chemother. 2017 Jul 1;72(7):2012-2019. (PMID: 28333342) Int J Antimicrob Agents. 2014 Sep;44(3):229-34. (PMID: 24985091) Antimicrob Agents Chemother. 2000 Oct;44(10):2600-3. (PMID: 10991830) J Infect Dis. 2015 Sep 15;212(6):990-8. (PMID: 25762787) J Biol Chem. 2014 May 2;289(18):12300-12. (PMID: 24497635) Sci Rep. 2018 Sep 10;8(1):13491. (PMID: 30202030) Bioinformatics. 2003 Jan 22;19(2):185-93. (PMID: 12538238) Annu Rev Microbiol. 2007;61:35-50. (PMID: 18035606) PLoS Pathog. 2015 Feb 12;11(2):e1004679. (PMID: 25675247) J Bacteriol. 2010 Mar;192(6):1662-70. (PMID: 20023019) J Clin Microbiol. 2011 Nov;49(11):3905-11. (PMID: 21900522) |
معلومات مُعتمدة: | NMRC/CSA/0050/2013 International National Medical Research Council; NMRC/TCR/011-NUHS/2014 International National Medical Research Council |
فهرسة مساهمة: | Keywords: Anti-tuberculosis drugs; Faropenem; Gene expression; Mechanism of action; Microarray; Transcriptome; Tuberculosis; Whole blood assay |
المشرفين على المادة: | 0 (Antitubercular Agents) 0 (Bacterial Proteins) 0 (Drug Combinations) 2KNI5N06TI (Pyrazinamide) 8G167061QZ (Ethambutol) V83O1VOZ8L (Isoniazid) VJT6J7R4TR (Rifampin) |
تواريخ الأحداث: | Date Created: 20200409 Date Completed: 20210406 Latest Revision: 20210406 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC7140558 |
DOI: | 10.1186/s12866-020-01766-y |
PMID: | 32264819 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1471-2180 |
---|---|
DOI: | 10.1186/s12866-020-01766-y |